N-(4-amino-butyl)-N-(4-{[4-(4-amino-butylamino)butylamino]-methyl}benzyl)butane-1,4-diamine trihydrochloride salt

ID: ALA557403

Chembl Id: CHEMBL557403

PubChem CID: 45266005

Max Phase: Preclinical

Molecular Formula: C24H49ClN6

Molecular Weight: 420.69

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  Cl.NCCCCNCCCCNCc1ccc(CNCCCCNCCCCN)cc1

Standard InChI:  InChI=1S/C24H48N6.ClH/c25-13-1-3-15-27-17-5-7-19-29-21-23-9-11-24(12-10-23)22-30-20-8-6-18-28-16-4-2-14-26;/h9-12,27-30H,1-8,13-22,25-26H2;1H

Standard InChI Key:  GXISTBPWRLTNBZ-UHFFFAOYSA-N

Associated Targets(Human)

Malme-3M (44254 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

L1210 (27553 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHO-MG (239 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHO (4503 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Pneumocystis carinii (749 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 420.69Molecular Weight (Monoisotopic): 420.3940AlogP: 2.08#Rotatable Bonds: 22
Polar Surface Area: 100.16Molecular Species: BASEHBA: 6HBD: 6
#RO5 Violations: 1HBA (Lipinski): 6HBD (Lipinski): 8#RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: 11.18CX LogP: 1.08CX LogD: -14.36
Aromatic Rings: 1Heavy Atoms: 30QED Weighted: 0.16Np Likeness Score: -0.13

References

1. Kaur N, Delcros JG, Imran J, Khaled A, Chehtane M, Tschammer N, Martin B, Phanstiel O..  (2008)  A comparison of chloroambucil- and xylene-containing polyamines leads to improved ligands for accessing the polyamine transport system.,  51  (5): [PMID:18281932] [10.1021/jm070794t]
2. Liao CP, Phanstiel O, Lasbury ME, Zhang C, Shao S, Durant PJ, Cheng BH, Lee CH..  (2009)  Polyamine transport as a target for treatment of Pneumocystis pneumonia.,  53  (12): [PMID:19805570] [10.1128/aac.00662-09]
3. Muth A, Kamel J, Kaur N, Shicora AC, Ayene IS, Gilmour SK, Phanstiel O..  (2013)  Development of polyamine transport ligands with improved metabolic stability and selectivity against specific human cancers.,  56  (14): [PMID:23841465] [10.1021/jm400496a]
4. Muth A, Madan M, Archer JJ, Ocampo N, Rodriguez L, Phanstiel O..  (2014)  Polyamine transport inhibitors: design, synthesis, and combination therapies with difluoromethylornithine.,  57  (2): [PMID:24405276] [10.1021/jm401174a]

Source